Plans for a new larger state-of-the-art facility to meet growing demand
hVIVO PLC (AIM:HVO) Notice of Results
hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will release its interim results for
Investors offload significant Chinese shares in an unprecedented sell-off.
Global investors are rapidly shedding their holdings in China’s premier stocks in an unprecedented sell-off, suggesting that even China’s top industries are no longer favoured due to economic uncertainties.
Omega Diagnostics Gp (AIM:ODX) Directorate Change
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health and Nutrition products, announces that Chris Lea, Group Finance Director of the Company, will be stepping down as
Beijing plans response to US investment prohibition
China is contemplating a retaliatory move in response to the recent surge of US sanctions that limit investments from US venture capital firms in advanced Chinese artificial intelligence (AI) companies.
Evgen Pharma (AIM:EVG) celebrates the potential new formulation of its leading candidate.
Evgen Pharma PLC (AIM: EVG) has revealed the conclusive data from its Phase 1b study, which evaluated the new enteric-coated tablet formulation of its primary drug, SFX-01.
Chinese property behemoth faces challenges, leading to market downturn
Asian stock markets declined due to troubles faced by China’s premier private real estate developer, raising fresh worries about the stability of the globe’s second-largest economy.
China experiences deflation, raising concerns for the worldwide economy
China has entered a phase of deflation as the world’s second-largest economy grapples with reigniting demand following prolonged zero-Covid strategies.
Evgen Pharma (AIM:EVG) shifts focus towards more lucrative collaborations as their partnership with JuvLife concludes.
Evgen Pharma PLC (AIM: EVG), a clinical-stage pharmaceutical development firm, has disclosed the termination of its patent and knowledge licence agreement with JuvLife Ltd, a subsidiary of Juvenescence Ltd.
AstraZeneca subsidiary finalizes a US$1bn deal with Pfizer for rare diseases.
AstraZeneca has reported a stronger-than-anticipated performance in the second quarter, with robust sales from its leading cancer drugs offsetting the decline in Covid vaccine sales.
hVIVO PLC (AIM & Euronext: HVO) Trading update
Strong first-half performance and record order book On track to deliver full-year guidance and long-term sustainable growth